Precigen (NASDAQ:PGEN) Trading Up 8.4% – What’s Next?

Precigen, Inc. (NASDAQ:PGEN) shares traded up 8.4% during trading on Tuesday . The company traded as high as $2.03 and last traded at $2.13. 502,453 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 2,153,742 shares. The stock had previously closed at $1.96.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research note on Tuesday, January 14th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Precigen Trading Down 3.0 %

The firm has a 50-day moving average price of $1.23 and a 200-day moving average price of $1.05. The company has a market capitalization of $576.95 million, a price-to-earnings ratio of -3.58 and a beta of 1.66.

Institutional Trading of Precigen

A number of hedge funds have recently bought and sold shares of PGEN. State Street Corp raised its position in Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after buying an additional 29,253 shares during the period. LexAurum Advisors LLC increased its holdings in shares of Precigen by 151.9% in the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock valued at $775,000 after purchasing an additional 417,055 shares during the period. Geode Capital Management LLC lifted its position in shares of Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after purchasing an additional 149,829 shares in the last quarter. Iridian Asset Management LLC CT boosted its holdings in shares of Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after purchasing an additional 1,706,815 shares during the period. Finally, Stifel Financial Corp grew its position in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 15,680 shares in the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.